Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase 3 trial in patients with gastroesophageal adenocarcinoma.
暂无分享，去创建一个
C. Fuchs | E. Van Cutsem | M. Mandalà | R. Cristescu | C. Shih | K. Muro | M. Ryu | H. Chung | C. Caglevic | Y. Bang | K. Shitara | M. Özgüroğlu | M. Di Bartolomeo | D. Aurora-Garg | Z. Cao | D. Adelberg | J. Kobie | J. Lu | J. Lu | J. Lu